CYP3A43 Pro 340 Ala polymorphism and prostate cancer risk in African Americans and Caucasians

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 5, 2005, Pages 1257-1261

  Stone, Angie ^a,g   Ratnasinghe, Luke D ^a,c,d   Emerson, Ginny L ^a   Modali, Rama ^f   Lehman, Terri ^f   Runnells, Gail ^c   Carroll, Alindria ^c   Carter, Weleetka ^c   Barnhart, Samuel ^c   Rasheed, Al A ^c   Greene, Graham ^c   Johnson, Don E ^b   Ambrosone, Christine B ^e   Kadlubar, Fred F ^a   Lang, Nicholas P ^b,c,d  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Arkansas Cancer Research Center   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f BioServe Biotechnologies Inc   (United States)

^g CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CARCINOGEN; CYTOCHROME P450 3A4; CYTOSINE; GUANINE; IMINO ACID; PROLINE DERIVATIVE; STEROID HORMONE;

AFRICAN AMERICAN; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CAUCASIAN; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AFRICAN AMERICANS; AGED; ALANINE; ARKANSAS; ARYL HYDROCARBON HYDROXYLASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROLINE; PROSTATIC NEOPLASMS;

EID: 20844444313     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0534     Document Type: Article

References (43)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002 Jan-Feb;52:23-47.
2. Erratum in: CA Cancer J Clin 2002 Mar-Apr;52:119.
3. CA Cancer J Clin 2002 May-Jun;52:181-2.
4. Crawford ED. Epidemiology of prostate cancer. Urology 2003;62:3-12.
5. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 2004;119:174-86.
6. Stat bite: Estimated deaths from selected cancers in the United States, 2004. J Natl Cancer Inst 2004;96:255.
7. Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 2003;97:1507-16.
8. Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995 Oct 25;274:1277-81.
9. Moul JW, Connelly RR, Mooneyhan RM, et al. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol 1999 Aug;162:394-7.
10. Mhatre AN, Trifiro MA, Kaufman M, et al. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat Genet 1993 Oct;5:184-8.
11. Erratum in: Nat Genet 1994 Feb;6:214.
12. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994 Aug 11;22:3181-6.
13. Jenster G, van der Korput HA, Trapman J, Brinkmann AO. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 1995 Mar 31;270:7341-6.
14. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999 Sep;20:1727-31.
15. Westlind A, Malmebo S, Johansson I, et al. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001 Mar 16;281:1349-55.
16. Finta C, Zaphiropoulos PG. Intergenic mRNA molecules resulting from trans-splicing. J Biol Chem 2002 Feb 22;277:5882-90. Epub 2001 Nov 28.
17. Gellner K, Eiselt R, Hustert E, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001 Mar;11:111-21.
18. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001 Feb;59:386-92.
19. Krusekopf S, Roots I, Kleeberg U. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol 2003 Apr 11;466:7-12.
20. Burk O, Wojnowski L. Cytochrome P 450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 2004 Jan;369:105-24. Epub 2003 Oct 21.
21. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998 Aug 9;90:1225-9.
22. Erratum in: J Natl Cancer Inst 1999 Jun 16;91:1082.
23. Paris PL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999 Oct;8:901-5.
24. Walker AH, Jaffe JM, Gunasegaram S, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in Brief No. 191. Online. Hum Mutat 1998;12:289.
25. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999 Sep;66:288-94.
26. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 Apr;27:383-91.
27. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003 Sep;12:928-32.
28. Cauffiez C, Lo-Guidice JM, Chevalier D, et al. First report of a genetic polymorphism of the cytochrome P450 3A43 (CYP3A43) gene: identification of a loss-of-function variant. Hum Mutat 2004 Jan;23:101.
29. Glykos NM, Cesareni G, Kokkinidis M. Protein plasticity to the extreme: changing the topology of a 4-α-helical bundle with a single amino acid substitution. Structure 1999;7:597-603.
30. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986 Jan;76:45-8.
31. Ross RK, Bernstein L, Lobo RA, et al. 5-α-Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992 Apr 11;339:887-9.
32. Ahluwalia B, Jackson MA, Jones GW, Williams AO, Rao MS, Rajgurus. Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer 1981 Nov 15;48:2267-73.
33. de Jong FH, Oishi K, Hayes RB, Bogdanowicz JF, Raatgever JW, van der Mass PJ. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. Cancer Res 1991 Jul 1;51:3445-50.
34. Santner SJ, Albertson B, Zhang GY, et al. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab 1998 Jun;83:2104-9.
35. Wang H, Dick R, Yin H, et al. Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry 1998 Sep 8;37:12536-45.
36. Ferrini RL, Barrett-Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 1998 Apr 15;147:750-4.
37. Plaskon LA, Penson DF, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev 2003 Jul;12:604-9.
38. Hickey K, Do KA, Green A. Smoking and prostate cancer. Epidemiol Rev 2001;23:115-25.
39. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. J Intern Med 2002 Sep;252:206-24.
40. Sharpe CR, Siemiatycki J. Joint effects of smoking and body mass index on prostate cancer risk. Epidemiology 2001 Sep;12:546-51.
41. Pickles T, Liu M, Berthelet E, Kim-Sing C, Kwan W, Tyldesley S. Prostate Cohort Outcomes Initiative. The effect of smoking on outcome following external radiation for localized prostate cancer. J Urol 2004 Apr;171:1543-6.
42. Oefelein MG, Resnick MI. Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer. J Urol 2004 Jun;171:2281-4.
43. Zeigler-Johnson CM, Walker A, Spangler E, et al. CYP3A4 and CYP3A5 genotypes: prevalence and association with prostate cancer etiology and severity. Proc AACR 2003 Jul;44:214.